A representative from the R&D tech provider offers advice on how to wrangle with a stressful, complicated process for better results and fewer headaches.
The company reports dosing of the first subject in a Phase IIa proof-of-concept study investigating a drug for an autism spectrum disorder related condition.
The National Institutes of Health grant to AVM Biotechnology will be used to evaluate a drug to treat non-Hodgkin’s lymphoma combined with standard of care.
The pharmaceutical company has completed acquisition of Turning Point Therapeutics, a company specializing in precision medicine solutions for cancer patients.
After scientists and reporters raised red flags about a study, Cassava Sciences is being accused of falsifying data in pursuit of an Alzheimer’s treatment.
Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.
This month’s announcements of appointments, partnerships, expansions, and mergers include Curia, Thread, TFF Pharmaceuticals, and other notable companies.
An expert from the trial tech firm explains how the 21st Century Cures Act and other recent regulatory advancements can elevate clinical data registries.
With updates to the Guideline for Good Clinical Practice Advancements on the horizon, an industry expert offers some perspective on what might be ahead.
During the World Orphan Drug Congress, a co-founder of the CRO outlined how patient perspective can be vital to better results in rare-disease research.
Bridging the Gap for Clinical Trials is a free competition designed to employ artistic expression to dispel misinformation start positive conversations.
The gathering, convened by patient advocacy group Fight Colorectal Cancer, responded to President Biden’s call to improve screening and treatment options.
The Foundation for Sarcoidosis Research hosted more than 50 agency leaders in a session that addressed patient concerns in research, care, and diagnosis.
A pediatric clinical trial expert from the CRO discusses the unique challenges involved in designing a study when the patients involved are little ones.
Taking place July 20, the Decentralized Trial Technology webinar will share insights and experiences from a group of knowledgeable virtual trial experts.
A leader from healthcare commercial intelligence company Definitive Healthcare discusses the rise of precision medicine and the benefits the field can yield.
In this second of a two-part series, a leader from the CRO discusses the types of technologies supporting DCTs and what might lie on the horizon for the field.
Biotech supply chains face an uncertain future in 2022 and beyond: up against myriad challenges ranging from future pandemic outbreaks to geopolitical tensions – and, indeed, unforeseen threats. Communication and collaboration between policymakers and...
The latest indepth report from the AI-centric analytics provider reveals nearly half of US cancer clinical studies enroll no Latino patient participants.
In this first of a two-part series, an expert discusses various factors behind the DCT format’s rapid rise and likely longevity in the drug development arena.
The academic research center has adopted the life science technology company’s cloud-based platform for cancer research, drug discovery, and clinical trials.
England's cost-effectiveness watchdog has recommended Eli Lilly’s Verzenios treatment as an option for adjuvant treatment of certain forms of breast cancer.
On July 20, a collection of noted industry experts will lead a lively discussion on the rapid evolution of DCTs, and what advances might be on the horizon.
The past two years have been full of shifts and shakes in the drug development field, but the change at Outsourcing-Pharma is easy and one for the better.
An expert from the decentralized trial solutions company shares how eCOA and ePRO can be useful tools that improve the collection and quality of such data.
The sponsorship from Janssen Pharmaceutical Companies will be used by the cancer support network to boost diversity in Phase I and Phase 2 clinical trials.
The company reports it has met the enrollment target for a trial of its sonic beam therapy, one step closer to submitting for FDA approval of the product.
If new restrictions are placed on the FDA’s Accelerated Approval pathway, as many as two thirds of the treatments that use this pathway would never reach patients, according to research released at the BIO International Convention last week.
During BIO International, US leaders shared lessons learned from COVID-19, and how government and industry are collaborating to avoid future supply chain crises.
Representatives from Clincierge, Rare Patient Voice, Insight and Measurement, and Ultragenyx Pharmaceutical will lead the lively panel discussion on June 13.
This year’s DIA Global Annual Meeting (taking place June 19-23 in Chicago) reunites professionals for face-to-face learning and networking opportunities.
Offering 13 topic tracks to choose from, the DIA Global Annual Meeting (scheduled June 19-23) lets attendees chose the path that fits their unique interests.
An expert from Rockwell Automation explains how integrating flexibility, using advanced technology, can help pharma manufacturing operations weather a storm.
During the upcoming BIO International Convention, experts from CerFlux, the MD Anderson Cancer Center, and Aga Khan University will weigh in with insights.
Coming back to the real world June 13-16, the industry event will offer face-to-face learning, networking opportunities, and fun, star-studded opportunities.
Efanesoctocog alfa is an investigational factor III therapy designed to prevent bleeds and bleeding episodes in patients diagnosed with the rare disorder.
The Lifebit CloudOS will be employed to create a Federate Trusted Research Environment within the center’s supercomputing cluster to handle data management.
Lithuania’s life sciences industry is growing at one of the fastest rates in Europe. Ahead of BIO, Innovation Agency Lithuania explains what the country’s plans are for future growth in the area and how this is built upon students heading into STEM studies.
The DATAcc has released a collection of open-access resources that are intended to help users build inclusivity into digital health measurement products.
The digital medicine solutions developer has received $300m in a Series D investment round, which will be used to help scale up its virtual care offerings.
The approval is the first that the Food and Drug Administration has granted for a drug intended to treat eosinophilic esophagitis, a chronic immune disorder.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, has awarded a total of $577m to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
The pharmaceutical company is partnering with Yseop to install the software company’s Augmented Analyst, designed to elevate and accelerate data analysis.
The agency has removed the hold placed on the pharmaceutical company’s IND for injectable lenacapavir, which is intended for HIV treatment and prevention.
The two companies are forming a European Medical Advisory Committee to better connect patients and physicians, inviting other trial professionals to join in.
Leaders from the biotech company share advice on how such organizations can make the most of often limited resources via smart strategy and collaboration.
The US agency has approved Enhertu for patients diagnosed with HER2-positive metastatic breast cancer previously treated with an anti-HER2-based regimen.
The US FDA released new draft guidance yesterday discussing, among other challenges, how unresolved product quality issues might be addressed in the context of regulatory decision-making.
The pharmaceutical firm and university have launched T-REX, a multi-year partnership focused on increasing health outcomes for underrepresented populations.
